Glucose Control in the (Neuro) Intensive Care Unit

Michael Moussouttas, MD
Department of Neurology, Thomas Jefferson University, Philadelphia, PA

Introduction
The vexing question of optimal glucose level in the intensive care unit has long perplexed intensivists. Hyperglycemia is a natural response to physiologic stress, and in the critically ill patient has been attributed to inflammatory processes, insulin counter-regulatory hormones, organ dysfunction, iatrogenic carbohydrate or medication related hyperglycemia, and insulin resistance as evidenced by concurrently elevated insulin levels. Hyperglycemia occurs in 50-75% of patients admitted to an ICU, and has been associated with various adverse outcomes including increased mortality, organ dysfunction, susceptibility to infections, and neurological complications. On the cellular level, tissue/organ damage is theorized to be mediated via the production of toxic polyol metabolites and reactive oxygen species, with compromise of mitochondrial/cellular function. At the opposite extreme, hypoglycemia is acutely detrimental and clearly mandates avoidance. Glucose variability has also been linked to adverse outcomes, and insulin administration itself has been associated with increased mortality. As such, it is believed that resolution of hypoglycemia, and not insulin administration, is the determinant of improved outcomes.

The dilemma facing intensive care physicians therefore lies in achieving a balance between the two detrimental extremes of hyperglycemia and hypoglycemia. Despite the completion of large randomized multicenter trials, the ideal glucose range to which treatment is targeted remains uncertain, and in fact there remains speculation as to whether glucose levels require treatment at all. Nevertheless, a familiarity with the available literature is imperative for the intensivist aspiring to achieve desirable outcomes for patients. The preponderance of literature pertaining to glycemic management in the ICU comes from non-neurological patients, and data regarding optimal glucose control in the NICU is therefore scant. As such, this article will review the available literature pertaining to hyperglycemic management in the ICU, with particular attention to patients with neurological conditions.

Complications of Hyperglycemia
Multiple studies have demonstrated an association between hyperglycemia and adverse outcomes, including mortality, and morbidity in terms of systemic multi-organ dysfunction and various adverse neurological outcomes. Systemic morbidity from hyperglycemia has included such adverse events as respiratory failure in the form of prolonged ventilator dependence, renal insufficiency, anemia and greater need for transfusions, and increased risk for infections and sepsis. Neurological consequences have involved elevations in intracranial pressure, cerebral herniation, greater frequency of epileptic episodes, ICU related polyneuromyopathy, and unfavorable outcomes based on measures of functional status. Hyperglycemia has been identified as a predictor of unfavorable outcomes in trauma patients, and in those with cardiovascular and cerebrovascular disease, and in SAH hyperglycemia has been related to the occurrence of vasospasm and poor outcome. Observational studies comparing intensive insulin therapy (IIT) to conventional therapy have suggested a possible benefit to IIT in terms of mortality and organ failure, obviating the need for more conclusive clinical trials.

Randomized Clinical Trials
Several large randomized trials have attempted to identify an optimal glucose range within which favorable outcomes are maximized and adverse events minimized. In a prospective, randomized, controlled (but unblinded) landmark study of 1548 SICU patients, IIT (target glucose levels 80-100mg/dl) was compared to conventional therapy (glucose 180-200mg/dl). Intensive therapy resulted in a lower mortality rate (4.6% vs. 8%), mostly in those with ICU stays >5 days, and mostly in those dying from sepsis and multi-organ failure. IIT also reduced overall in-hospital mortality, duration of ventilator dependence, acute renal failure, hyperbilirubinemia, anemia, bacteremia, and critical illness polynuropathy.

In a follow-up study with similar methodology (but blinded) of 1200 MICU patients, IIT to keep glucose levels between 80-110mg/dl was compared to conventional therapy aiming at levels below 180mg/dl. In this study, IIT had no impact upon mortality, yet reduced duration of ventilatory support, acute renal failure, and ICU stay. Interestingly, among patients treated with IIT, those who stayed in the ICU for 3 or more days had less in-hospital mortality whereas those staying for less time had increased in-hospital mortality, and those staying for 7 or more days had lower rates of neurological complications. IIT patients also experienced more episodes of hypoglycemia, which may have been in part due to the greater frequency of patients with renal and hepatic failure in the MICU.

In a randomized unblinded single-center study of 504 MICU and SICU patients, treatment strategies comparing goal glucose levels between 80-110mg/dl and 180-200mg/dl were compared. Mortality rates were similar between the two (36.6% vs. 32.4%), but hypoglycemic episodes were greater in the IIT group (8.5% vs. 1.7%).

In the VISEP study of over 600 septic patients, which was terminated prematurely for safety reasons, IIT [glucose 80-110mg/dl] was associated with a greater rate of severe hypoglycemia (17% vs. 4.1%) and more frequent serious adverse events (10.9% vs. 5.2%), red-cell transfusions, and duration of ICU stay, than conventional therapy [180-200mg/dl].

The GLUCONTROL study of 1078 medical and surgical ICU patients was also terminated prematurely due to safety reasons and excessive protocol violations, but demonstrated that IIT [glucose 80-110mg/dl] versus intermediate glucose control [140-180mg/dl] resulted in similar mortality rates (15.3% vs. 17.2%). Hypoglycemic events were also increased by IIT (8.7% vs. 2.7%), and a greater mortality was observed in these patients. The NICE-SUGAR study of 6104 general ICU patients

---

* Volume Substitution and Insulin Therapy in Severe Sepsis
† Normoglycemia in Intensive Care Evaluation—Survival Using
revealed an increased mortality rate among IIT patients [glucose 80-110mg/dl, 27.5% mortality] compared to conventional therapy [140-180mg/dl, 24.9% mortality] and greater rates of hypoglycemia (6.8% vs.0.5%).18

**Neurological Patients**

In a subgroup analysis of patients with cerebral injury from the original SICU study, most of whom experienced a cerebrovascular event or had neurosurgery for various reasons, IIT resulted in a reduction in intracranial pressures, epileptic episodes, critical illness polyneuropathy, need for vasopressors, and diabetes insipidus.6 In a small study of head trauma patients, IIT resulted in more hypoglycemic events, but no improvement in mortality, neurological outcome, or infections.19

One retrospective study of patients with subarachnoid hemorrhage showed no benefit to aggressive hyperglycemic management in terms of neurological outcome, vasospasm and delayed cerebral ischemia.20

A prospective observational microdialysis study of SAH patients found elevated glucose levels to be associated with increased lactate/pyruvate ratios and increased mortality.21 Conversely, a more recent study of head trauma patients showed that IIT resulted in lower cerebral glucose concentrations (without a change in cerebral glucose metabolic rate), with increases in global oxygen extraction fraction.22 This study also showed elevated lactate/pyruvate ratios, and increased glutamate concentrations in patients treated with IIT, particularly with serum glucose levels below 80mg/dl.22 Mortality did not differ between the intensive and regular insulin therapy groups.22

**Review Articles and Meta-Analyses**

A review article focusing on the VISEP, GLUCONETROL, and NICE-SUGAR studies concluded that the available evidence supports treatment of glucose levels >180mg/dl, thus effectively discouraging aggressive glycemic control as defined by most clinical trials, and notes the potential for maximum benefit at levels <140mg/dl.3 In assessing the available data cumulatively, a 2008 meta-analysis of over 8000 patients concluded that IIT reduces risk for Septicemia, but at the expense of more hypoglycemic episodes (<40mg/dl) and without any impact on in-hospital mortality.4 Current guidelines for critically ill patients presented by the American Diabetes Association recommend starting treatment at glucose levels >180mg/dl, with a goal of maintaining levels <140mg/dl, and discourage aggressive treatment to reach levels <110mg/dl.23

**Conclusions**

Despite the clear association between hyperglycemia and adverse outcomes, clinical studies have failed to definitively provide evidence for a benefit to antihyperglycemic therapy, and certainly have not identified a precise target range for glucose levels. This leads one to wonder whether hyperglycemia may represent a physiological protective response, and therefore a natural evolutionarily derived reaction to illness that does not mandate treatment. As recently stated by one author, “the ultimate proof that hyperglycemia is an independent risk factor for ICU mortality in critically ill patients is lacking”.3,9

As is the case with many situations in medicine, there is an innate belief that “abnormal” laboratory values warrant correction. Until the completion of trials demonstrating the absence of benefit (and in fact a detriment) from transfusions for anemia in ICU patients, the belief was to normalize hemoglobin counts so as to maintain levels of 10 or greater. Now, with the completion of adequate trials, the standard of care has become to allow hemoglobin levels as low as 7.24 Thus, this tendency to treat “abnormal” glucose values may actually counteract a natural reactive (and possibly protective) process, which may simply represent the natural inclination by physicians to assume a need for treatment of aberrant values.